Bioscience

← Back

Prof. Melissa Kapulu

Principal Investigator


Publications

Undertaking Community Engagement for a Controlled Human Malaria Infection Study in Kenya: Approaches and Lessons Learnt.
Mumba, N., Njuguna, P., Chi, P., Marsh, V., Awuor, E., Hamaluba, M., Mauncho, C., Mwalukore, S., Masha, J., Mwangoma, M., Kalama, B., Alphan, H., Wambua, J., Bejon, P., Kamuya, D., Kapulu, M. C.
Front Public Health, (2022). 10:793913

Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.
Williams, E., Craig, K., Chiu, C., Davies, H., Ellis, S., Emerson, C., Jamrozik, E., Jefford, M., Kang, G., Kapulu, M., Kolstoe, S. E., Littler, K., Lockett, A., Elena, Rey, Messer, J., McShane, H., Saenz, C., Selgelid, M. J., Shah, S., Smith, P. G., Yamazaki, N.
Vaccine, (2022). 40:3484-3489

Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response.
Kapulu, M. C., Kimani, D., Njuguna, P., Hamaluba, M., Otieno, E., Kimathi, R., Tuju, J., Sim, B. K. L., CHMI-SIKA Study Team
BMC Infect Dis, (2022). 22:86

Ethical considerations around volunteer payments in a malaria human infection study in Kenya: an embedded empirical ethics study.
Chi, P. C., Owino, E. A., Jao, I., Bejon, P., Kapulu, M., Marsh, V., Kamuya, D.
BMC Med Ethics, (2022). 23:46

Shigella-Controlled Human Infection Models: Current and Future Perspectives.
Clarkson, K. A., Porter, C. K., Talaat, K. R., Kapulu, M. C., Chen, W. H., Frenck, R. W., Bourgeois, A. L., Kaminski, R. W., Martin, L. B.
Curr Top Microbiol Immunol, (2022). :

Controlled Human Malaria Infection Studies in Africa-Past, Present, and Future.
Kibwana, E., Kapulu, M., Bejon, P.
Curr Top Microbiol Immunol, (2022). :

Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.
Musasia, F. K., Nkumama, I. N., Frank, R., Kipkemboi, V., Schneider, M., Mwai, K., Odera, D. O., Rosenkranz, M., Furle, K., Kimani, D., Tuju, J., Njuguna, P., Hamaluba, M., Kapulu, M. C., Wardemann, H., CHMI-SIKA Study Team., Osier, F. H. A.
Nat Commun, (2022). 13:4098

Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study.
Kimingi, H. W., Kinyua, A. W., Achieng, N. A., Wambui, K. M., Mwangi, S., Nguti, R., Kivisi, C. A., Jensen, A. T. R., Bejon, P., Kapulu, M. C., Abdi, A. I., Kinyanjui, S. M., CHMI-SIKA Study Team
Front Immunol, (2022). 13:894770

Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study.
Kapulu, M. C., Nakakana, U., Sciré, A. S., Sarakinou, E., Conti, V., Rossi, O., Acquaviva, A., Necchi, F., Obiero, C. W., Martin, L. B., Bejon, P., Njuguna, P., Micoli, F., Podda, A.
Front Immunol, (2022). 13:971866

Engagement of ethics and regulatory authorities on human infection studies: Proceedings of an engagement workshop in Zambia.
Kunda-Ng'andu, E. M., Simuyandi, M., Kapulu, M., Chirwa-Chobe, M., Mwanyungwi-Chinganya, H., Mwale, S., Chilengi, R., Sharma, A.
Wellcome Open Res, (2021). 6:31